论文部分内容阅读
目的观察应用酮体芬和布地奈德(普米克都保)联合治疗咳嗽变异型哮喘(CVA)的临床疗效。方法将86例患者随机分组,治疗组43例给予口服酮体芬片及布地奈德吸入剂,对照组43例给予口服氨茶碱片。结果治疗组显效30例(69.8%),有效12例(27.9%),无效1例(2.3%),总有效率高达97.7%。对照组显效21例(48.8%),有效8例(18.6%),无效14例(32.6%),总有效率为67.4%。结论酮体芬和布地奈德治疗CVA疗效显著,方法简便,未发现明显毒副反应,值得临床应用和推广。
Objective To observe the clinical efficacy of ketorolac combined with budesonide (PUMIC) in the treatment of cough variant asthma (CVA). Methods Totally 86 patients were randomly divided into treatment group (43 cases), oral ketoprofen tablets and budesonide inhalation, and control group (43 cases) were given oral aminophylline tablets. Results The treatment group was markedly effective in 30 cases (69.8%), effective in 12 cases (27.9%), ineffective in 1 case (2.3%), the total effective rate was as high as 97.7%. Control group, 21 cases (48.8%), effective in 8 cases (18.6%), invalid in 14 cases (32.6%), the total effective rate was 67.4%. Conclusion The efficacy of ketoprofen and budesonide in the treatment of CVA is remarkable, the method is simple, and no obvious side effects have been found, which is worthy of clinical application and promotion.